Benitec Biopharma Inc. (BNTC)
| Market Cap | 394.73M +7.2% |
| Revenue (ttm) | n/a |
| Net Income | -41.54M |
| EPS | -0.93 |
| Shares Out | 34.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 103,035 |
| Open | 11.37 |
| Previous Close | 11.85 |
| Day's Range | 11.00 - 11.81 |
| 52-Week Range | 9.85 - 17.15 |
| Beta | 0.28 |
| Analysts | Strong Buy |
| Price Target | 27.00 (+134.99%) |
| Earnings Date | May 14, 2026 |
About BNTC
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disea... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for BNTC stock is "Strong Buy." The 12-month stock price target is $27.0, which is an increase of 134.99% from the latest price.
News
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 2...
Benitec Biopharma initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $25 price target BB-301 represents “an exciting opportunity in the rare disease space,” particularly for treat...
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the ...
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genet...
Benitec Biopharma announces interim Phase 1b/2a study of BB-301
Benitec Biopharma (BNTC) announced “promising” interim clinical results from the BB-301 Phase 1b/2a first-in-human study evaluating low dose and high dose BB-301 treatment for Oculopharyngeal Muscular...
Benitec Biopharma reports Q2 EPS (26c) vs (26c) last year
“We continue to be encouraged by the benign safety profile and the durability of efficacy demonstrated in our BB-301 clinical development program,” said Jerel Banks, M.D., Ph.D., Executive Chairman an...
Benitec Biopharma files to sell 1.48M shares of common stock for holders
The company will not receive any of the proceeds from the sale of the common stock by the selling stockholders.
Benitec Biopharma first patient treated in Cohort 1 of BB-301 Phase 1b/2a study
Benitec Biopharma (BNTC) announced that the first patient treated in Cohort 1 of the BB-301 Phase 1b/2a clinical study evaluating BB-301 for the treatment of dysphagia in oculopharyngeal muscular dyst...
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with dee...
Benitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Benitec Biopharma (BNTC) to $32 from $35 and keeps a Buy rating on the shares. The firm cites the…
Benitec Biopharma reports Q1 EPS (22c), consensus (33c)
“We are fortunate to have achieved several important milestones this year. We previously announced positive interim clinical study results from the Phase 1b/2a trial of BB-301, with a 100% responder…
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
– Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use i...
Benitec Biopharma $100M share Spot Secondary priced at $13.50
The deal range was $13.00-$13.50. Leerink, TD Cowen and Evercore ISI acted as joint book running managers for the offering.
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel ge...
Benitec Biopharma announces common stock offering, no amount given
Benitec Biopharma (BNTC) announced that it has commenced an underwritten public offering of its common stock and intends to conduct a concurrent registered direct offering of its common stock with…
Benitec Biopharma Inc. Announces Proposed Public Offering
HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel ge...
Benitec Biopharma price target raised to $35 from $28 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Benitec Biopharma (BNTC) to $35 from $28 and keeps a Buy rating on the shares. The company reported “highly positive” interim data…
Benitec Biopharma price target raised to $22 from $20 at Citizens JMP
Citizens JMP raised the firm’s price target on Benitec Biopharma (BNTC) to $22 from $20 and keeps an Outperform rating on the shares. Benitec presented a 100% response rate for…
Benitec provide interim clinical results for BB-301 Phase 1b/2a trial of BB-301
Benitec Biopharma (BNTC) provides positive interim clinical results for the BB-301 Phase 1b/2a Clinical Trial. Following administration of BB-301, Cohort 1 patients demonstrated significant and sustai...
Benitec Biopharma appoints Mates to board of directors
Benitec Biopharma (BNTC) announces the appointment of Dr. Sharon Mates to the board of directors of the Company, effective November 2, 2025. Sharon Mates previously served as the Chairman, Chief…
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel geneti...
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST
Benitec Biopharma files $200M mixed securities shelf
17:17 EDT Benitec Biopharma (BNTC) files $200M mixed securities shelf
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Exp...
Benitec Biopharma price target lowered to $29 from $35 at Oppenheimer
Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on Benitec Biopharma (BNTC) to $29 from $35 and keeps an Outperform rating on the shares. Since the last corporate update…